AccuraGen China passed the PT of 2019-nCoV nucleic acid testing

Created on:
February 25, 2020

Since Shanghai Yunsheng Medical Laboratory (fully owned subsidiary of AccuraGen Holdings) joined ‘againste pidemic and anti-virus joint action’ on the day of February 2nd. We kept a close eye on the national epidemic situation, provided employee-education, initiated daily health reporting, and actively participated in the ‘2019-nCoV nucleic acid detection capability verification’ organized by SCCL. 


In the first half of February, Shanghai Yunsheng Medical Laboratory arranged local employees who had no travel history and close contacts of COVID-19 patients to participate online training such as clinical testing of 2019-nCoV. On February 23rd, Yunsheng passed the quality evaluation of 2019-nCoV nucleic acid proficiency testing (PT). In the qualitative testing project, our results are completely consistent with the standards. Under the co-ordination of the control center, Shanghai Yunsheng joined the"anti-epidemic" campaign in response to government calls. 


Shanghai AccuraGen Biotechnology Co., Ltd. and Shanghai Yunsheng Medical Laboratory continue to provide professional services to its collaborative partners.

All Journal Posts